Tejas Patil

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Tejas Patil
Apr 23, 2025, 07:40 | Blog
Tejas Patil: MET and NF2 Alterations Linked to Primary Resistance in ALK TKI Therapy
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X…
Dec 8, 2024, 02:56 | Insight
Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X:…
Dec 2, 2024, 10:22 | Blog
Tejas Patil: The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in non-small cell lung cancer
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, posted on X about recent…
Nov 25, 2024, 17:49 | Insight
Tejas Patil: Why biomarkers like PDL1 and TMB aren’t always associated with ‘hot’ or ‘cold’ immune TME
Tejas Patil, Thoracic oncologist CU Cancer Center, shared a post by Cancer Cell on X:…
Nov 22, 2024, 22:09 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Oct 14, 2024, 13:40 | Insight
Retrospective report on EGFR mutant NSCLC transformed to SCLC, suggested by Stephen V Liu
Stephen V Liu shared a post on X: "Retrospective report in European Journal of Cancer on…
Jul 25, 2024, 21:48 | Insight
Stephen V Liu: What is the role for SRS to brain metastases up front for EGFR or ALK NSCLC?
Stephen V Liu shared a paper by Luke R.G. Pike et al. on X, adding: “What…
Jul 25, 2024, 14:02 | Insight
Erman Akkus: Should up-front SRS be added to TKI in brain metastatic EGFR/ALK positive NSCLC?
Erman Akkus, Medical Oncologist at Ankara University, shared a paper by Luke R.G. Pike et al. on…
Jul 21, 2024, 13:36 | Blog
Rami Manochakian: Neoadjuvant osimertinib in stage I-IIIA EGFRm NSCLC did not meet primary endpoint
Rami Manochakian shared a post on X: ''Hot off the press. Neoadjuvant Osimertinib for the…
Jul 12, 2024, 15:14 | Blog
Tejas Patil: Delighted to have contributed the ALK dataset to this AI study
Tejas Patil, Thoracic oncologist CU Cancer Center, made the following post on X: "Delighted to…
Jul 11, 2024, 14:39 | Insight
Tejas Patil: DeepPT predicts tumor mRNA expression from hematoxylin and eosin slides
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a paper by Danh-Tai…
Jul 10, 2024, 16:42 | Blog
Yakup Ergün: The effects of 960 mg sotorasib
Tejas Patil, Thoracic oncologist CU Cancer Center, shared a post by Yakup Ergün, Medical Oncologist at Antalya…
All: 12 Posts: 1 - 100
Special Coverage